Biohaven Ltd (NYSE: BHVN) on Monday, plunged -4.29% from the previous trading day, before settling in for the closing price of $15.61. Within the past 52 weeks, BHVN’s price has moved between $12.79 and $55.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -49.78% annually for the last half of the decade. The company achieved an average annual earnings per share of 17.86%. With a float of $92.38 million, this company’s outstanding shares have now reached $105.78 million.
In an organization with 256 employees, it is important to assess its efficiency.
Biohaven Ltd (BHVN) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Biohaven Ltd is 12.68%, while institutional ownership is 82.69%. The most recent insider transaction that took place on Mar 04 ’25, was worth 996,238. In this transaction Director of this company bought 32,700 shares at a rate of $30.47, taking the stock ownership to the 2,320,571 shares. Before that another transaction happened on Dec 30 ’24, when Company’s Director bought 29,000 for $35.94, making the entire transaction worth $1,042,393. This insider now owns 2,368,741 shares in total.
Biohaven Ltd (BHVN) Performance Highlights and Predictions
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1.74 earnings per share (EPS) for the period falling under the consensus outlook (set at -1.55) by -0.19. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.14% during the next five years compared to -49.78% drop over the previous five years of trading.
Biohaven Ltd (NYSE: BHVN) Trading Performance Indicators
Biohaven Ltd (BHVN) is currently performing well based on its current performance indicators. A quick ratio of 3.82 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -7.66, a number that is poised to hit -1.88 in the next quarter and is forecasted to reach -5.93 in one year’s time.
Technical Analysis of Biohaven Ltd (BHVN)
Let’s dig in a bit further. During the last 5-days, its volume was 2.6 million. That was better than the volume of 1.72 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 64.42%.
During the past 100 days, Biohaven Ltd’s (BHVN) raw stochastic average was set at 19.03%, which indicates a significant decrease from 63.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.88 in the past 14 days, which was lower than the 1.21 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.44, while its 200-day Moving Average is $27.45. However, in the short run, Biohaven Ltd’s stock first resistance to watch stands at $15.61. Second resistance stands at $16.27. The third major resistance level sits at $16.61. If the price goes on to break the first support level at $14.61, it is likely to go to the next support level at $14.27. Assuming the price breaks the second support level, the third support level stands at $13.61.
Biohaven Ltd (NYSE: BHVN) Key Stats
Market capitalization of the company is 1.58 billion based on 105,791K outstanding shares. Right now, sales total 0 K and income totals -846,420 K. The company made 0 K in profit during its latest quarter, and -198,150 K in sales during its previous quarter.
